Citizens JMP analyst Jonathan Wolleben raised the firm’s price target on Ocular Therapeutix (OCUL) to $29 from $20 and keeps an Outperform rating on the shares. New details on a derisked pivotal program in Nonproliferative Diabetic Retinopathy allows value to be ascribed to the potential blockbuster opportunity while the wet AMD pivotal readouts will drive near-term value creation, the analyst tells investors in a research note.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCUL:
- Ocular Therapeutix’s Strategic Initiatives and Clinical Advancements Drive Buy Rating
- Ocular Therapeutix Announces $475M Stock Offering
- Ocular Therapeutix prices 37.9M shares at $12.53 in underwritten offering
- Ocular Therapeutix Updates on AXPAXLI Clinical Trials
- Ocular Therapeutix files automatic mixed securities shelf